A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2020-09, Vol.34 (9), p.2489-2492
Hauptverfasser:	Bose, Prithviraj, Verstovsek, Srdan, Cortes, Jorge E., Tse, Susan, Gasior, Yvonne, Jain, Nitin, Jabbour, Elias J., Estrov, Zeev, Alvarado, Yesid, DiNardo, Courtney D., Pemmaraju, Naveen, Kornblau, Steven M., Kadia, Tapan M., Daver, Naval G., Naqvi, Kiran, Short, Nicholas J., Masarova, Lucia, Villareal, John, Pierce, Sherry A., Nogueras-Gonzalez, Graciela, Huang, Xuelin, Garcia-Manero, Guillermo, Kantarjian, Hagop M., Ravandi, Farhad
Format:	Artikel
Sprache:	eng
Schlagworte:	5-aza-2'-deoxycytidine 631/67/1990/2331 692/699/67/1990/2331 Acute myeloid leukemia Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer Research Critical Care Medicine Decitabine - administration & dosage Dose-Response Relationship, Drug Enzyme inhibitors Female Hematology Humans Intensive Internal Medicine Letter Leukemia Leukemia, Myeloid, Acute - drug therapy Male Medicine Medicine & Public Health Middle Aged Myeloid leukemia Myeloproliferative Disorders - pathology Neoplasms, Second Primary - drug therapy Nitriles Oncology Oncology, Experimental Pyrazoles - administration & dosage Pyrimidines Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!